Announcements Trials
Browse Landscape

Phase

Phase 2 261Phase 1 141Phase 1/2 86Phase 3 53Phase 4 16Phase NA 11Phase 2/3 7Phase EARLY_PHASE1 5

Status

Recruiting 3Withdrawn 1Unknown 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 5INDUSTRY 2

Study Type

Interventional 7

Sponsor

Cancer Type

NET 2Gastrointestinal 2Endocrine 2Gynecologic 1

Conditions

Tuberous Sclerosis 2Autistic Disorder 2Uterine Neoplasms 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Intellectual Disability 1Hamartoma Syndrome, Multiple 1Gastroenteropancreatic Neuroendocrine Tumors 1Gallbladder Neoplasms 1Adenoma, Islet Cell 1

Interventions

Cisplatin 98Gemcitabine 66Paclitaxel 62Carboplatin 60Fluorouracil 59Docetaxel 59Capecitabine 59Oxaliplatin 56Cyclophosphamide 54Radiotherapy 50Drug Therapy 46Bevacizumab 38pembrolizumab 35Dexamethasone 33Magnetic Resonance Spectroscopy 32Leucovorin 32Doxorubicin 31Cytarabine 27Etoposide 26Pemetrexed 25Nivolumab 24Methotrexate 24Radiation 20Vincristine 18venetoclax 17apatinib 17Rituximab 17Prednisone 17Letrozole 17Irinotecan 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 2/3 × Everolimus × Clear all
NCT07165886 2026-04-24

Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2/3 Recruiting
298 enrolled
EndocrineGastrointestinalNET

Gastroenteropancreatic Neuroendocrine Tumors

NCT06943755 2026-04-17

STELLAR-311

Exelixis

Phase 2/3 Recruiting
440 enrolled
EndocrineNET

Adenoma, Islet Cell, Neoplasm Metastasis, Neuroendocrine Tumors

NCT07218575 2025-10-20

Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations

Boston Children's Hospital

Phase 2/3 Not yet recruiting
60 enrolled

Autistic Disorder, Hamartoma Syndrome, Multiple

NCT05833815 2024-08-13

Addition of Everolimus to Standard of Care in Carcinoma Gallbladder

Banaras Hindu University

Phase 2/3 Recruiting
56 enrolled
Gastrointestinal

Gallbladder Neoplasms

NCT02860494 2021-05-03

EVEROST

Hospices Civils de Lyon

Phase 2/3 Withdrawn

Tuberous Sclerosis

NCT03285802 2020-02-05

Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation

Greater Baltimore Medical Center

Phase 2/3 Completed
1 enrolled
Gynecologic

Uterine Neoplasms

NCT01730209 2015-05-05

RAPIT

Erasmus Medical Center

Phase 2/3 Unknown
60 enrolled

Autistic Disorder, Intellectual Disability, Tuberous Sclerosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡